Dewpoint Therapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dewpoint Therapeutics pioneers drug discovery targeting biomolecular condensates — liquid-like protein assemblies implicated in cancer, neurodegeneration, and metabolic disease; raised over $160M;
About
Dewpoint Therapeutics is a Boston-based biotechnology company founded in 2018 by Richard Young, Tony Hyman, and Clifford Brangwynne — three of the world's leading researchers in the science of biomolecular condensates. Condensates are dynamic, liquid-like assemblies of proteins and nucleic acids that form within cells through a process called phase separation. Dewpoint's thesis is that many diseases — including cancer, neurodegeneration, and metabolic disorders — involve the dysregulation of these condensates, and that drugs targeting condensate behavior represent a new class of therapies beyond conventional target-based drug discovery.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Dewpoint Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.